The OVATION-2 Study may be an option for you. The OVATION-2 Study is evaluating an investigational immunotherapy combined with traditional standard of care (chemotherapy and surgery) treatment, compared to standard of care treatment alone, in women with newly diagnosed or suspected late-stage ovarian cancer.
*Standard of care treatment — Standard of care, or best practice, is a guideline for the appropriate treatment of a condition, as established by formal or informal consensus among experts on that condition. Basically, the standard of care for the treatment of a disease is whatever most physicians agree is the best way to treat that disease.
If you have not yet started standard of care treatment, this study may be an option for you.
The OVATION-2 Study is enrolling women who’ve just been diagnosed with, or are currently being tested for, stage 3 or 4 (advanced) ovarian, fallopian tube, or primary peritoneal cancer and are looking for an opportunity to potentially try both the standard of care (chemotherapy and surgery) treatment plus an investigational immunotherapy treatment.
You may be eligible for the OVATION-2 Study if you:
Have just been diagnosed with, or are currently being tested for, stage 3 or 4 epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
Have not yet started cancer treatment
Have never received treatment for any abdominal or pelvic tumor before
Have not had any other form of cancer in the past three years
Are ambulatory (able to walk around) and generally capable of self-care